cagrilintide: Clinical Trials

18 trials of cagrilintide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 5 active not recruiting, 2 recruiting, 1 not yet recruiting. 18 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 318Completed 10, Active not recruiting 5, Recruiting 2, Not yet recruiting 1

Follow cagrilintide: new trials by email Literature Review of cagrilintide trials Research Report on cagrilintide

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
CagriSema, Semaglutide, Cagrilintide - Hypertension, Obesity
Phase 3Not yet recruitingNovo Nordisk A/S14082026-11-112026-11-05
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Cagrilintide, Placebo cagrilintide, Placebo semaglutide - Overweight, Obesity
Phase 3RecruitingNovo Nordisk A/S2852026-08-042026-09-04
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Cagrilintide, Semaglutide, Placebo cagrilintide - Overweight, Obesity
Phase 3RecruitingNovo Nordisk A/S4602026-01-082026-09-30
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Cagrilintide, Placebo - Obesity, Overweight
Phase 3Active not recruitingNovo Nordisk A/S3002025-11-052026-08-06
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Cagrilintide, Placebo (matched to Cagrilintide) - Overweight, Obesity
Phase 3Active not recruitingNovo Nordisk A/S3302025-11-052026-11-16
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity
Phase 3Active not recruitingNovo Nordisk A/S4002025-02-102026-01-20
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Cagrilintide, Semaglutide, Tirzepatide - Diabetes Mellitus, Type 2
Phase 3CompletedNovo Nordisk A/S10232024-11-052026-10-19
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo - Obesity
Phase 3CompletedNovo Nordisk A/S3002024-06-242026-05-05
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Cagrilintide, Semaglutide, Placebo - Type 2 Diabetes
Phase 3CompletedNovo Nordisk A/S2742024-03-262026-09-09
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Cagrilintide, Semaglutide, Placebo - Type 2 Diabetes
Phase 3CompletedNovo Nordisk A/S1892024-03-192026-09-30
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Cagrilintide, Semaglutide, Tirzepatide - Type 2 Diabetes
Phase 3CompletedNovo Nordisk A/S10242024-01-162026-10-19
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Cagrilintide, Semaglutide, Tirzepatide - Obesity
Phase 3CompletedNovo Nordisk A/S8092023-11-272026-02-06
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Cagrilintide, Semaglutide, Placebo cagrilintide - Type 2 Diabetes Mellitus
Phase 3CompletedNovo Nordisk A/S27342023-09-272026-11-19
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo Semaglutide - Obesity or Overweight
Phase 3CompletedNovo Nordisk A/S3002023-08-152026-01-09
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo Semaglutide - Obesity or Overweight
Phase 3CompletedNovo Nordisk A/S3312023-04-032026-01-22
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Cagrilintide, Semaglutide, Placebo - Cardiovascular Disease
Phase 3Active not recruitingNovo Nordisk A/S71012023-03-012026-08-31
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo cagrilintide - Overweight, Obesity
Phase 3CompletedNovo Nordisk A/S12002023-02-012026-01-28
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity
Phase 3Active not recruitingNovo Nordisk A/S34002022-11-012026-09-30

Conditions studied

Obesity (12)  ·  Diabetes Mellitus, Type 2 (7)  ·  Overweight (7)  ·  Cardiovascular Diseases (1)  ·  Hypertension (1)

Sponsors

Novo Nordisk A/S (18)

Countries

United States (16)  ·  Canada (11)  ·  United Kingdom (10)  ·  Poland (9)  ·  Argentina (8)  ·  Australia (8)  ·  Germany (8)  ·  Hungary (8)  ·  India (7)  ·  Italy (7)  ·  Japan (7)  ·  Serbia (7)  ·  Denmark (6)  ·  South Africa (6)  ·  Spain (6)

Results publications

PMID 40544432, PMID 40544433, PMID 41328546, PMID 42009015, PMID 42251856, PMID 42251859, PMID 42251860, PMID 42838477

NIH funding

2023 (4), 2025 (1)